NewLink cuts 30% of staff to continue indoximod development

Along with a second quarter earnings announcement, NewLink Genetics revealed a corporate restructuring Tuesday meant to support the development of its beleaguered immunotherapy indoximod, as well as cut costs. NewLink expects to spend $10 million per quarter after the restructuring.